Davood KHoda Amorzideh on VTE and Bleeding in Cancer
Davood KHoda Amorzideh, Clinical Cardiologist at Farjam Heart Clinic, shared on LinkedIn:
”In the AVERT post-hoc analysis, cancer patients at intermediate-high VTE risk (Khorana_score ≥2) with elevated baseline GDF_15 had increased VTE risk, while elevated NT proBNP and CRP levels predicted bleeding.
Increasing hs-TnT levels from baseline to 1 month was associated with increased VTE risk.
Steven Hawken, Marc Carrier, Philip Wells, Dylan Burger, Tzu-Fei Wang’‘
Read the full article here.
Article: Venous thromboembolism and bleeding in cancer patients: role of inflammatory and cardiac biomarkers Open Access
Authors: Danielle Carole Roy , Tzu-Fei Wang , Ranjeeta Mallick , Dylan Burger , Marc Carrier , Philip Wells , Steven Hawken
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 31, 2026, 16:35IV Thrombolysis Does Not Improve Vision in Acute CRAO: Ahmed Koriesh on TenCRAOS Study
-
Jan 31, 2026, 16:24Joyce John Chalakkal: The Dangerous Area of The Face….
-
Jan 31, 2026, 16:04Rayya Saadiq Reflects On Qatar Health Congress 2026
-
Jan 31, 2026, 15:12Amar Raval on Oral Thin Film Drug Delivery Systems for Thrombosis Therapy
-
Jan 31, 2026, 14:40Heghine Khachatryan on WFH’s Call to Advance Health Equity for People with Bleeding Disorders
-
Jan 31, 2026, 14:10Emilia Arturo: Snake Venom, Clotting, and CryoEM!
-
Jan 31, 2026, 08:13Ming Y Lim On The Value of National Mentorship
-
Jan 31, 2026, 06:37Christian Schulze Presents The Post-Hoc Analysis of the DanGer Shock Trial
-
Jan 31, 2026, 06:27Negative Trials Matter: Anne Hege Aamodt Shares The TenCRAOS Trial